Clinical Data Analysis
Bring New Drugs to Market Faster with Early, Hands-On Analysis
Pharmaceutical companies are focused on "failing faster" to save time, energy, and money and focus their attention on the most viable drug candidates. They can fail faster by identifying non-viable candidates earlier in phase 1 and 2. They can identify these non-starters if early data can be easily visualized and shared, so researchers can identify critical risks and make informed decisions about patterns, trends, and outliers.
For example, clinical pharmacologists who perform phase 1 "first time in human" studies for a promising new cancer drug execute many testing iterations and review dosage tests with multiple users with diverse skill sets for each iteration. Preparing the data for these reviews requires collation from such sources as drug metabolism, pharmacokinetics, and safety lag. The data needs to be presented visually, where it is easy to identify patterns and trends. Researchers need to plot lab tests against each other, view vital signs, dosage, and event data. They need to work with sensitive parameters even as the study is running, such as combining blood pressure data or visualizing safety data such as liver function.
Physicians, pharmacokineticists, study leaders, statisticians, and data managers use TIBCO visualization technology to instantly access, share, and manipulate visualizations on the fly. Physicians quickly identify anomalies and explore individual patient trends as well as trends across the patient population. Costs are reduced, and attrition rates in phase 3 clinical trials are improved because informed decisions are made to fail non-viable candidates earlier in phase 1.
